The S&P 500 remains a powerful wealth-building tool, but future returns may be subdued due to valuation headwinds. Read more about the indexing approach.

From cabbies to the Czech Republic ...

A developer-targeting campaign leveraged malicious Next.js repositories to trigger a covert RCE-to-C2 chain through standard ...

Q4 2025 Earnings Call February 20, 2026 5:00 AM ESTCompany ParticipantsAude Rodriguez - Head of Investor RelationsFrançois ...

Colour is among the most potent design tools – but one that architects can underuse. A RIBAJ/Dulux roundtable set out to discuss how to harness its power beneficially across a range of settings ...

Maternal mortality remains disproportionately high in low-income and middle-income countries, where pyramidal health systems ...

Information on the NSERC USRA Competition for Summer 2026 is now available. The Natural Sciences and Engineering Research Council of Canada (NSERC) is a federal agency responsible for promoting and ...

Suchandrima Bhowmik has written over 300 articles on various health conditions, medical news, and recent breakthroughs. Her work appears in several publications, including Medical News Today, ...

Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...

Background: Many individuals seek health-related guidance through ChatGPT OpenAI (San Francisco, CA, USA), due to its convenience and perceived reliability, often in place of, or as a supplement to, ...

(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...